<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05798195</url>
  </required_header>
  <id_info>
    <org_study_id>2023-ZF-3</org_study_id>
    <nct_id>NCT05798195</nct_id>
  </id_info>
  <brief_title>Traditional Chinese Medicine or Low-dose Dexamethasone in COVID-19 Pneumonia</brief_title>
  <official_title>Traditional Chinese Medicine or Low-dose Dexamethasone in Symptomatic Patients With Post-COVID-19 Parenchymal Lung Abnormalities: a Randomized Controlled Trial Three Arm, Parallel Group, Single Blind, Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China-Japan Friendship Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this type of clinical trial is to learn about symptomatic patients with&#xD;
      post-COVID-19 parenchymal lung abnormalities. The main questions it aims to answer are: the&#xD;
      efficacy and safety of low-dose dexamethasone or traditional Chinese medicine in symptomatic&#xD;
      patients with post-COVID-19 parenchymal lung abnormalities.&#xD;
&#xD;
      Participants will be divided into three parallel groups：controlled group with conventional&#xD;
      western medicine treatment including oxygen therapy, antibiotics, nebulization therapy, etc.&#xD;
      dexamethasone group: dexamethasone 1.5mg/day for one week and 0.75mg/day for another week&#xD;
      basing on conventional western medicine. Chinese medicine group: Strengthening spleen and&#xD;
      tonifying lung decoction for 2 weeks basing on conventional western medicine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lung CT scan</measure>
    <time_frame>1 month</time_frame>
    <description>compared with base,≥90% pneumonia obsorbed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung CT scan</measure>
    <time_frame>3 months</time_frame>
    <description>compared with base,≥50% pneumonia obsorbed</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>controlled group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional western medicine treatment including oxygen therapy, antibiotics, nebulization therapy, etc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexamethasone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dexamethasone 1.5mg/day for one week and 0.75mg/day for another week basing on conventional western medicine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chinese medicine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Strengthening spleen and tonifying lung decoction for 2 weeks basing on conventional western medicine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>conventional western medicine treatment</intervention_name>
    <description>conventional western medicine treatment only</description>
    <arm_group_label>Chinese medicine group</arm_group_label>
    <arm_group_label>controlled group</arm_group_label>
    <arm_group_label>dexamethasone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone oral tablet</intervention_name>
    <description>treat with Dexamethasone for 2 weeks</description>
    <arm_group_label>dexamethasone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Traditional Chinese medicine decoction</intervention_name>
    <description>treat with strengthening spleen and tonifying lung decoction for 2 weeks</description>
    <arm_group_label>Chinese medicine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of COVID-19 pneumonia；&#xD;
&#xD;
          -  3 to 8 weeks after the onset of the first symptoms of COVID-19 infection;&#xD;
&#xD;
          -  Modified Medical Research Council (mMRC) score ⩾2 or hypoxemia;&#xD;
&#xD;
          -  Imaging severity assessment of pneumonia: CT severity scores (CTSS):≥5；&#xD;
&#xD;
          -  Signed the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants still admitted to intensive care unit at the time of enrollment;&#xD;
&#xD;
          -  Known prior structural lung disease, including pulmonary fibrosis, severe COPD, severe&#xD;
             bronchiectasis, and lung destruction;&#xD;
&#xD;
          -  Taking glucocorticoids or immunosuppressants because of other chronic diseases;&#xD;
&#xD;
          -  Contraindications of glucocorticoid;&#xD;
&#xD;
          -  Heart failure(NYHA III or IV);&#xD;
&#xD;
          -  Participants with renal replacement therapy;&#xD;
&#xD;
          -  Psychiatric disorders or cognitive impairments;&#xD;
&#xD;
          -  The expected survival time is less than six months due to diseases other than COVID-19&#xD;
             pneumonia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhenguo Zhai, Dcotor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Respiratory and Critical Care Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wanmu Xie, Doctor</last_name>
    <phone>86-10-84206246</phone>
    <email>xiewanmu@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanmu Xie, Doctor</last_name>
      <phone>86-10-84206246</phone>
      <email>xiewanmu@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>April 2, 2023</study_first_submitted>
  <study_first_submitted_qc>April 2, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>April 2, 2023</last_update_submitted>
  <last_update_submitted_qc>April 2, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China-Japan Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Zhenguo Zhai,MD,PhD</investigator_full_name>
    <investigator_title>Chief physician of PCCM</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

